Andrew Obenshain is the Chief Executive Officer of bluebird bio, a biotechnology company that develops gene therapies for severe genetic disorders.
Andrew Obenshain is the Chief Executive Officer of bluebird bio, a biotechnology company that develops gene therapies for severe genetic disorders. He previously served as president of the company's genetic diseases business. Obenshain leads bluebird bio's efforts to advance therapies for rare diseases.
Full founder directory · Investor directory · Company funding database · Fundraising library
The Startup Fundraising Platform
Raise funds for your startup
Find the right investors and get real replies — instantly, powered by AI.
Takes 30 seconds · No credit card · Cancel anytime
Slide-by-slide guide